Biomind Labs Inc (BMND) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Biomind Labs Inc (BMND) has a cash flow conversion efficiency ratio of 0.028x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-48.96K ≈ $-35.42K USD) by net assets (CA$-1.74 Million ≈ $-1.26 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See BMND net asset quality index to measure how much of total assets are equity-financed.
Biomind Labs Inc - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how Biomind Labs Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Biomind Labs Inc (BMND) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Biomind Labs Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biomind Labs Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Wonpung Mulsan Co.Ltd
KQ:008290
|
-0.087x |
|
Agrogeneration
PA:ALAGR
|
-0.030x |
|
Fastator AB
ST:FASTAT
|
0.055x |
|
ILYA Co. Ltd
KQ:058450
|
-0.047x |
|
Mannatech Incorporated
NASDAQ:MTEX
|
0.347x |
|
Taitron Components Incorporated
NASDAQ:TAIT
|
0.026x |
|
BSL Corp Bhd
KLSE:7221
|
0.024x |
|
Zyrexindo Mandiri Buana PT Tbk
JK:ZYRX
|
0.108x |
Annual Cash Flow Conversion Efficiency for Biomind Labs Inc (2021–2025)
The table below shows the annual cash flow conversion efficiency of Biomind Labs Inc from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see BMND market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CA$-1.74 Million ≈ $-1.26 Million |
CA$-67.55K ≈ $-48.86K |
0.039x | -85.72% |
| 2024-12-31 | CA$-1.30 Million ≈ $-940.54K |
CA$-354.43K ≈ $-256.39K |
0.273x | -49.03% |
| 2023-12-31 | CA$-1.43 Million ≈ $-1.04 Million |
CA$-765.93K ≈ $-554.06K |
0.535x | -93.84% |
| 2022-12-31 | CA$-247.66K ≈ $-179.15K |
CA$-2.15 Million ≈ $-1.56 Million |
8.685x | +997.29% |
| 2021-12-31 | CA$2.19 Million ≈ $1.59 Million |
CA$-2.12 Million ≈ $-1.54 Million |
-0.968x | -- |
About Biomind Labs Inc
Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. The company is developing BMND01, which is in Phase II clinical trials for use in the treatment of depression; BMND08, a 5-Metoxi-N,N-dimethyltryptamine sublingual formulation that is in Phase II clinical… Read more